GlassScriptPhysician profile
Sandra M Lee
NPI 1689014995
$7,316.71
in general payments reported to CMS, 2019-2025
30 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $921 · 2022: $1,522 · 2023: $1,926 · 2024: $1,830 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,483 · Education: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,482.89 |
| Education | $390.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,640.74 | 2021-2025 | |
| Janssen Biotech, INC. | $997.22 | 2021-2025 | Tremfya, Remicade, Simponi |
| Lilly USA, LLC | $723.76 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $580.68 | 2021-2025 | |
| Ucb, INC. | $439.02 | 2022-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $331.48 | 2022-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $304.46 | 2022-2025 | Sotyktu |
| Pfizer INC. | $299.05 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $273.23 | 2021-2025 | Jublia, Siliq |
| Galderma Laboratories, L.P. | $273.02 | 2021-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $242.67 | 2021-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $197.36 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $164.32 | 2021-2024 | Winlevi, Absorica Ld |
| Genzyme Corporation | $113.13 | 2021-2025 | |
| Leo Pharma INC. | $106.48 | 2021-2023 | Adbry |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $103.04 | 2021-2022 | |
| Kyowa Kirin, INC. | $88.61 | 2022-2024 | Poteligeo |
| Amgen INC. | $56.67 | 2023-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $56.37 | 2023 | |
| Organon LLC | $54.51 | 2025 | Nexplanon |
| Journey Medical Corporation | $42.62 | 2021-2022 | |
| Medtronic, INC. | $39.08 | 2024-2025 | Ligasure, Eea |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.98 | 2023 | Spevigo |
| Mayne Pharma Commercial LLC | $28.54 | 2021 | |
| Dermira, INC. | $25.18 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.20 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $21.02 | 2024 | Crysvita |
| Botanix Sb INC | $19.69 | 2025 | Sofdra |
| Cipher Pharmaceuticals US LLC | $18.13 | 2025 | Spinosad, Natroba |
| Epi Health, LLC | $15.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.